-
Mashup Score: 5Shifting Treatment Goals, Timelines in Primary Biliary Cholangitis - 4 month(s) ago
In this video segment, Reau, Trivedi, and Hirschfield discuss recent shifts in treatment goals for patients with PBC and a new focus on timely intervention with second-line options.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0FDA Grants Accelerated Approval to Seladelpar (Livdelzi) for Primary Biliary Cholangitis - 4 month(s) ago
The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
The FDA has granted accelerated approval to @GileadSciences seladelpar (Livdelzi) for the treatment of #PBC in combination with UDCA in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. Learn more: https://t.co/U2l7f1HrnF https://t.co/yQG52DDLeB
-
-
Mashup Score: 0FDA Grants Accelerated Approval to Seladelpar (Livdelzi) for Primary Biliary Cholangitis - 4 month(s) ago
The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
The FDA has granted accelerated approval to @GileadSciences seladelpar (Livdelzi) for the treatment of #PBC in combination with UDCA in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. Learn more: https://t.co/U2l7f1HrnF https://t.co/yQG52DDLeB
-
-
Mashup Score: 0FDA Grants Accelerated Approval to Elafibranor (Iqirvo) for PBC - 6 month(s) ago
The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
ICYMI: Earlier this week, the FDA granted accelerated approval to elafibranor (Iqirvo) 80 mg tablets for the treatment of #PBC based on phase 3 data showing its impact on ALP reduction. Learn more: https://t.co/b9owa4kVlO https://t.co/fWIgvpfxXs
-
-
Mashup Score: 1
Late-breaking phase 3 data presented at EASL show elafibranor’s impact on managing PBC progression and improving itch-related quality of life in patients with pruritus.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
New data from the phase 3 ELATIVE trial demonstrate the efficacy of elafibranor in managing #PBC progression after 78 weeks of treatment, with results additionally showing its potential to improve itch-related quality of life. Learn more: https://t.co/9WJBy9LUAY
-
-
Mashup Score: 0
International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the challenges that patients with this rare liver disease face and how their stories can help advance diagnosis, treatment and care. A relatively rare disease, both in the United States and worldwide, PBC affects an estimated 65 out of the 100,000 women in the U.S., according to the American
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
‘Ask me about #PBC’ campaign calls on patients to speak up for rare #liverdisease #InternationalPBCDay https://t.co/irmbWC2iCN
-
-
Mashup Score: 0
The phase 3 seladelpar investigator discusses the current landscape of care available for patients with PBC.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
From the first part of our Q&A with @DrCynthiaLevy on the state of #PBC burden and treatment: what is the role of ALP management? Read here: https://t.co/DStFb3jxVX https://t.co/JFx53Nztju
-
-
Mashup Score: 0
In a Healio video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on primary biliary cholangitis presented at EASL Congress, including risk factors for disease progression and seladelpar for treatment of pruritis.In a retrospective analysis, Kremer and colleagues examined 1,111 patients with primary biliary cholangitis (PBC) who received ursodeoxycholic acid as first-line
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
In a @GoHealio #GI video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on #PBC presented at #EASLCongress ( @EASLnews), including risk factors for disease progression and #seladelpar for treatment of #pruritis. https://t.co/xcx1s22G94
-
-
Mashup Score: 7Managing Primary Biliary Cholangitis: An Expert Exchange - 3 year(s) ago
Are you optimally monitoring your patients with primary biliary cholangitis (PBC)?
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Are you optimally monitoring your patients with primary biliary cholangitis? #PBC #CME #MedTwitter https://t.co/oOsrnPdSnu https://t.co/vclmCUJRgB
-
-
Mashup Score: 2Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes - 3 year(s) ago
We read with interest the work by Mansoor et al 1 regarding the outcomes of COVID-19 in coeliac disease. The impact of pre-existing chronic liver diseases on COVID-19 outcomes has been largely evaluated,2–4 and consequently specific recommendations have been made in these patients.5 However, the relationship between primary biliary cholangitis (PBC) and SARS-CoV-2 remains unknown.6 We aimed to…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
RT @joaprimo: Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes https://t.co/1PQNDHR2fU #PBC…
-
Following the FDA accelerated approval of seladelpar (Livdelzi) for the treatment of #PBC, @CholestasisDoc @NancyReau and Gideon Hirschfield, PhD, MB BChir discussed the evolving landscape of PBC management in this 6-part HCPLive Special Report: https://t.co/5eRNdaLRoo https://t.co/zbAkTcbuhE